Performance of AclarusDx™, a Blood-Based Transcriptomic Test for AD, in US Patients Newly Referred to a Memory Center

Mild Cognitive Impairment Clinical Trial

Official title:

Performance of AclarusDx™, A Blood-Based Transcriptomic Test for Alzheimer's Disease, in US-based Patients Suffering From Memory Impairment and Newly Referred to A Reference Memory Center, for AD Diagnostic Workup—A Pilot Descriptive Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01465360
• Other study ID #: EHTAD/003
• Status: Completed
• Phase: N/A
• First received: October 28, 2011
• Last updated: July 4, 2012
• Start date: November 2011

Study information

• Verified date: July 2012
• Source: Exonhit
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Observational

Clinical Trial Summary

The purpose of this study is to assess the performance of AclarusDx™, an investigational blood test detecting gene expression information, and intended to help physicians in making an Alzheimer's Disease diagnosis in patients having memory impairments.

Description:

The objective of this study is to apply AclarusDx™ signature in a reference US Center in 160 patients newly referred to one of the three study centers within the Cleveland Clinic, Center for Brain Health network, for diagnostic workup. Only AclarusDx™ will be added to the panel of tests usually performed at the centers to establish diagnosis. AclarusDx™ will be used for investigational use only, not for diagnostic purpose. The ultimate goal is to define the clinical utility of AclarusDx™ to provide Primary Care Physicians (PCPs) with a tool that will help them in making the diagnosis of Alzheimer's Disease (AD).

The primary objectives are :

1. To obtain an estimate of the capability of AclarusDx™ to identify AD patients among a US-based population of newly referred patients suffering from objective memory impairment which maybe potentially related to multiple and different etiologies.

2. To compare the performance of AclarusDx™ in a US-based population of newly referred patients with memory impairment with the performance of AclarusDx™ observed in one comparable European population.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 160
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 21 Years and older

Eligibility

Inclusion Criteria:

• Male or female patient referred to the center for memory impairment.

• The memory impairment has previously been observed by a caregiver or documented by a physician.

• The memory impairment is confirmed by the memory center.

• Caucasian ethnicity.

• A written informed consent approved by an ethical review board or similar body must be obtained from the patient prior to any study-related procedures.

• If applicable, standard treatment with cholinesterase inhibitor and/or memantine is acceptable.

• Patient estimated to be compliant with study procedures.

• Patient has a level of understanding sufficient to agree to all procedures required by the protocol and must be able to cooperate. Under no circumstances will a subject who does not understand the procedure, be allowed to consent to the procedure.

Exclusion Criteria:

• Recent acute pathology or medical condition or surgery which may alter the inflammatory homeostasis, according to the opinion of the investigator.

• Non-Caucasian ethnicity.

• Patient with severe uncontrolled or unstable medical condition.

• Need for a legal representative for the medical condition of the patient.

• Any current pathology or medical condition, for which blood sampling may involve a risk for the patient's health, according to the opinion of the investigator.

• Current or recent history (within one month) of clinically significant pathology, medical condition (including hospitalization) or symptoms. However, chronic diseases or medical conditions that are considered stable are accepted, provided that they are compatible with other study selection criteria.

• Current or recent history of drug or alcohol abuse or dependence.

• Current, clinically significant major psychiatric disorder (eg, major depressive disorder) according to the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition text revised (DSM-IV TR), or significant symptoms (eg, hallucinations).

• Woman of childbearing potential is not allowed to participate in the study. (A woman of childbearing potential is a woman who is biologically capable of becoming pregnant).

• Current participation in another study using an investigational non-marketed product.

Study Design

Observational Model: Case-Only, Time Perspective: Cross-Sectional

Related Conditions & MeSH terms

• Alzheimer Disease
• Alzheimer's Disease
• Aphasia
• Aphasia, Primary Progressive
• Cognition Disorders
• Dementia
• Dementia, Vascular
• Fronto-temporal Dementia
• Frontotemporal Dementia
• Mild Cognitive Impairment
• Mixed Dementia
• Parkinson Disease
• Parkinson' Disease Dementia
• Pick Disease of the Brain
• Primary Progressive Aphasia
• Vascular Dementia

Locations

Country	Name	City	State
United States	Cleveland Clinic Center for Brain Health - Mellen Center	Cleveland	Ohio
United States	Cleveland Clinic Senior Care Assessment - Lakewood Hospital	Lakewood	Ohio
United States	Cleveland Clinic Lou Ruvo Center for Brain Health	Las Vegas	Nevada

Sponsors (1)

Lead Sponsor	Collaborator
Exonhit

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Sensitivity of AclarusDx™ in AD patients	The determination of the sensitivity of the test, being the percentage of positive AclarusDx™ calls among referred patients being confirmed clinically as having AD at the Memory Center will be calculated.	Outcome measured during one single study visit	No

External Links

•   Sponsor website